[Effects of xamoterol in moderate cardiac insufficiency].
Xamoterol, a partial agonist of beta 1-adrenoceptors, was tested as a cardiotonic drug in 10 patients with moderate chronic heart failure. The trial was double-blind drug versus placebo for 3 months and open for one year. At 3 months the patients were clinically improved with downgrading by one NYHA class, and there was a significant increase in response to a 36-second exercise, as compared with the placebo group. Haemodynamic index, a 14 per cent fall in pulmonary wedge pressure and a 7 per cent increase in left ventricular stroke work as compared with the placebo group. This clinical and haemodynamic improvement was paralleled by a reduction of the double product on exercise. In long term use, xamoterol did not seem to induce tachyphylaxis, and few side-effects were recorded during this trial.
Kayanakis
J G
JG
Clinique cardiologique Paulmy, Bayonne.
Larouchi
L
L
Doat
P
P
Grenet
B
B
Fauvel
J M
JM
Bounhoure
J P
JP
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011412:Propanolamines / Q000494:pharmacology*; D011897:Random Allocation; D017307:Xamoterol
D000318:Adrenergic beta-Agonists; D010919:Placebos; D011412:Propanolamines; D017307:Xamoterol
Effets du xamotérol dans l'insuffisance cardiaque modérée.